U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H28ClF3N4O2
Molecular Weight 557.006
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TELACEBEC

SMILES

CCC1=C(N2C=C(Cl)C=CC2=N1)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(OC(F)(F)F)C=C5

InChI

InChIKey=OJICYBSWSZGRFB-UHFFFAOYSA-N
InChI=1S/C29H28ClF3N4O2/c1-2-25-27(37-18-22(30)7-12-26(37)35-25)28(38)34-17-19-3-8-23(9-4-19)36-15-13-21(14-16-36)20-5-10-24(11-6-20)39-29(31,32)33/h3-12,18,21H,2,13-17H2,1H3,(H,34,38)

HIDE SMILES / InChI

Molecular Formula C29H28ClF3N4O2
Molecular Weight 557.006
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Q203 (6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl)imidazo [1,2-a]pyridine-3-carboxamide) is an an imidazopyridine antitubercular compound. Q203 targets the cytochrome b subunit (QcrB) of the cytochrome bc1 complex. This complex is an essential component of the respiratory electron transport chain of ATP synthesis. Q203 inhibited the growth of multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis clinical isolates in culture broth medium in the low nanomolar range and was efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body weight, which highlights the potency of this compound. In addition, Q203 displays pharmacokinetic and safety profiles compatible with once-daily dosing. Q203 is a promising new clinical candidate for the treatment of tuberculosis.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P9WP37
Gene ID: 887400.0
Gene Symbol: qcrB
Target Organism: Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.92 μg/mL
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
Q-203 plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1490 ng/mL
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
Q-203 plasma
Mus musculus
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
23.91 μg × h/mL
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
Q-203 plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
44100 ng × h/mL
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
Q-203 plasma
Mus musculus
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23.4 h
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
Q-203 plasma
Mus musculus
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2
unhealthy, ADULT
Health Status: unhealthy
Condition: pulmonary tuberculosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources: Page: p.2
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
unlikely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

The Phase I clinical trial (clinicaltrials.gov identifier: NCT02530710) enrolling healthy patients is a dose-escalation study starting at 100 mg dosing that will be adjusted based on PK analysis.
Route of Administration: Oral
Q203 inhibited the growth of multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis clinical isolates in culture broth medium in the low nanomolar range
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:30:01 GMT 2023
Edited
by admin
on Sat Dec 16 08:30:01 GMT 2023
Record UNII
55G92WGH3X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TELACEBEC
INN   USAN  
Official Name English
TELACEBEC [USAN]
Common Name English
telacebec [INN]
Common Name English
6-CHLORO-2-ETHYL-N-((4-(4-(4-(TRIFLUOROMETHOXY)PHENYL)-1-PIPERDINYL)PHENYL)METHYL)-IMIDAZO(1,2-A)PYRIDINE-3-CARBOXAMIDE
Systematic Name English
Q203
Code English
Telacebec [WHO-DD]
Common Name English
Q-203
Code English
IMIDAZO(1,2-A)PYRIDINE-3-CARBOXAMIDE, 6-CHLORO-2-ETHYL-N-((4-(4-(4-(TRIFLUOROMETHOXY)PHENYL)-1-PIPERIDINYL)PHENYL)METHYL)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C280
Created by admin on Sat Dec 16 08:30:02 GMT 2023 , Edited by admin on Sat Dec 16 08:30:02 GMT 2023
FDA ORPHAN DRUG 499015
Created by admin on Sat Dec 16 08:30:02 GMT 2023 , Edited by admin on Sat Dec 16 08:30:02 GMT 2023
FDA ORPHAN DRUG 793920
Created by admin on Sat Dec 16 08:30:02 GMT 2023 , Edited by admin on Sat Dec 16 08:30:02 GMT 2023
Code System Code Type Description
SMS_ID
300000034390
Created by admin on Sat Dec 16 08:30:02 GMT 2023 , Edited by admin on Sat Dec 16 08:30:02 GMT 2023
PRIMARY
CAS
1334719-95-7
Created by admin on Sat Dec 16 08:30:02 GMT 2023 , Edited by admin on Sat Dec 16 08:30:02 GMT 2023
PRIMARY
NCI_THESAURUS
C152543
Created by admin on Sat Dec 16 08:30:02 GMT 2023 , Edited by admin on Sat Dec 16 08:30:02 GMT 2023
PRIMARY
PUBCHEM
68234908
Created by admin on Sat Dec 16 08:30:02 GMT 2023 , Edited by admin on Sat Dec 16 08:30:02 GMT 2023
PRIMARY
FDA UNII
55G92WGH3X
Created by admin on Sat Dec 16 08:30:02 GMT 2023 , Edited by admin on Sat Dec 16 08:30:02 GMT 2023
PRIMARY
USAN
FG-22
Created by admin on Sat Dec 16 08:30:02 GMT 2023 , Edited by admin on Sat Dec 16 08:30:02 GMT 2023
PRIMARY
INN
10573
Created by admin on Sat Dec 16 08:30:02 GMT 2023 , Edited by admin on Sat Dec 16 08:30:02 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET ORGANISM->INHIBITOR
TARGET -> INHIBITOR
IN-VITRO
Scientific Literature
Related Record Type Details
ACTIVE MOIETY